Navigation Links
Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
Date:1/28/2009

LUGANO, Switzerland, January 28 /PRNewswire/ -- Today the Swiss pharmaceutical group Helsinn announced the acquisition, of the US biopharmaceutical company, Sapphire Therapeutics Inc. with headquarters in Bridgewater, New Jersey, for an undisclosed amount.

The establishment of a US-based R&D and commercial operation represents attainment of one of the Helsinn Group's corporate strategic goals. "We are thrilled at this very important opportunity to increase Helsinn's value with a direct presence in the major pharmaceutical market of the world," said Riccardo Braglia, CEO of the Helsinn Group. "The acquisition of Sapphire Therapeutics will also allow us to expand our current pipeline of products in existing, focused therapeutic areas, in particular in Cancer Supportive Care. This is a major step forward for the growth of Helsinn into the future with the new subsidiary Helsinn Therapeutics (US) Inc.," he concluded.

Sapphire Therapeutics Inc. was founded in 2000 and is focused on developing first-in-class, composition-of-matter protected products for the treatment of a variety of cancer, gastrointestinal and metabolic conditions. "Sapphire Therapeutics Inc. and its staff have proven pharma and biotech expertise and all of us are extremely excited of becoming part of the Helsinn Group," commented William J. Polvino, CEO of Sapphire Therapeutics (US) Inc.

Helsinn has appointed Franco De Vecchi, who is already a member of Helsinn Holding's Board, to become Chairman and President of Helsinn Therapeutics (US) Inc. to manage all of the existing staff who will be maintained and strengthened.

This acquisition will give the Helsinn Group access to a very interesting and promising pipeline of products:

- anamorelin, a first-in-class therapy for the treatment of cancer cachexia, suitable for once-a-day oral administration, with early evidence of a rapid onset of beneficial ef
'/>"/>

SOURCE Helsinn Healthcare SA
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... , , NEW YORK, Dec. 1 /PRNewswire/ ...search report is available in its catalogue: ,,...pe: Market dynamics and the changing healthcare an...linker.com/p0165658/Emerging-Clinical-Trial-Locati...ing-healthcare-and-regulatory-environment.html ,...
(Date:12/1/2009)... , , CAMBRIDGE, Mass., Dec. 1 /PRN...tic biology industry and to promote its potential,...e formation of the Synthetic Biology Industry Asso...week. The goal of the association is to provide a ...discuss the new industry, address its opportunitie...
(Date:12/1/2009)... , , SHANGHAI, Dec. 1 /PRNewswire-As...diary of ShangPharma, a leading China-based Contra... is a winner of the 2009 Deloitte,Technology Fast ...rowing high,tech companies in China. The award is ...r revenue growth from 2006 to 2008. , The...
(Date:12/1/2009)... , , SPRINGFIELD, Ill., Dec. 1 /PRNews...), is proud to announce that it was recently award...e Awards event on Nov. 13 in New York City. The CL...e and innovation in the healthcare advertising ind...of the world,s most recognized awards competitions...
Breaking Biology Technology:Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 3Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 2
... that every company wanted to avoid: The Vapor Lis...nd then publisher of PC Letter, the List counted t..., years) between the time a software product was a.... , ,At a time when dozens of new companies were s...orm, the list was Stewart,s way of calling softwar...
...eak" in Iraq, Matt Storms is ready to continue his...ious columns covered due diligence and corporate c...ll Business Innovation Research (SBIR) and Small B...k Matt for his service, and we thank him for the f...Once you complete your due diligence and corporat...
...lecommunications Professionals of Wisconsin is con... , a networking and business support organization ...rganization said the partnership "reflects the inc...ons sector and the information technology sector a...every sector of the regional, national and world e...
Other Biology Technology:Is Beta the new Vapor? 2Is Beta the new Vapor? 3Is Beta the new Vapor? 4Raising capital through placement agents 2Raising capital through placement agents 3Raising capital through placement agents 4Accelerate Madison to merge with Telecommunications Professionals 2
(Date:12/2/2009)...arette smoking and alcohol consumption before head...atient,s future risk of death, according to publis...milar effect among those who continued these habit...rs are counseled to quit smoking; despite this, ma... to smoke even after their cancer diagnosis, incre...
(Date:12/2/2009)...xposure to secondhand smoke for a prolonged period...k of breast cancer, even in women who never smoked...her exposure to side-stream smoke could increase r...aid Peggy Reynolds, Ph.D., senior research scienti...eley office. "While no single epidemiologic study ...
(Date:12/2/2009)... beef, peanut butter, and other foods have done mo...ood safety. They also are quietly fueling a boom i...ing new food safety regulations. That,s the topic ...f Chemical & Engineering News , (C&EN) ACS, weekl...Kemsley and Senior Correspondent Marc Reisch point...
Breaking Biology News(10 mins):Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2Exposure to secondhand cigarette smoke over a lifetime increased breast cancer risk later in life 2Oncothyreon announces appointment of Douglas E Williams Ph D to board of directors 14352 1Oncothyreon announces appointment of Douglas E Williams Ph D to board of directors 14352 2Methodist Hospital Adopts New Technology Solutions to Improve Care for California Patients and Reduce Operating Costs 5220 1Methodist Hospital Adopts New Technology Solutions to Improve Care for California Patients and Reduce Operating Costs 5220 2Methodist Hospital Adopts New Technology Solutions to Improve Care for California Patients and Reduce Operating Costs 5220 3Methodist Hospital Adopts New Technology Solutions to Improve Care for California Patients and Reduce Operating Costs 5220 4Facilitation Payments Seen as Problematic by Many Companies 5215 1Facilitation Payments Seen as Problematic by Many Companies 5215 2Facilitation Payments Seen as Problematic by Many Companies 5215 3Facilitation Payments Seen as Problematic by Many Companies 5215 4
...ectious Diseases (NAID), one of the National Insti...versity of Washington (UW) to use systems biology ...e virus-host interactions and cellular response ne...se of acute respiratory virus infection. , This n...ze, UW professor of microbiology and associate dir...
... body,s cells normally auto-destruct may play a ro...rch published online in the journal Apoptosis a...programmed cell death. , Doctors know that geneti...cts nearly everyone older than 60, as well as many...genes are known to play a role in congenital deafn...
...uence , Both natural and human-induced influence...r relative roles and regional impacts are still un...point to increasing human-generated greenhouse gas...of global surface warming after 1967, while some e...ccounts for as much as 69 percent of warming seen ...
Other Biology News:NIAID funds studies of how SARS and bird flu evade antiviral responses 2Genes that control cell death fingered in age-related hearing loss 2Genes that control cell death fingered in age-related hearing loss 3AGU journal highlights -- Oct. 16, 2008 2AGU journal highlights -- Oct. 16, 2008 3AGU journal highlights -- Oct. 16, 2008 4AGU journal highlights -- Oct. 16, 2008 5AGU journal highlights -- Oct. 16, 2008 6AGU journal highlights -- Oct. 16, 2008 7
Rabbit Anti-Human IRF7 Antibody, Unconjugated from ABR-Affinity BioReagents
Rabbit Anti-PI3K p110 delta (Poly6049) Polyclonal Antibody, Unconjugated from BioLegend
Rabbit Anti-Human Retinoic Acid-Induced 3 (RAI3 / RAIG1) Polyclonal Antibody, Unconjugated from IMGENEX
Mouse Anti-Human CD164 Antibody, Biotin Conjugated from BioLegend
Biology Products: